(+/-)-Sotalol hydrochloride, >=98% (TLC), powder

Application

(±)-Sotalol hydrochloride has been used to test its effect on the cardiac action potential (AP) in human hearts. It has also been used as an β- blocker to determine its effect on free intracellular calcium (Ca²⁺) release and whole-cell currents in mammalian cancer cells.

Biochem/physiol Actions

Potent β-adrenoceptor antagonist; class III antiarrhythmic; prolongs the action potential and increases the refractory period.

Sotalol has a potential to block non-cardioselective β-adrenergic receptors. It acts as an anti-arrhythmic agent and is used as a therapeutic for equine arrhythmias. In addition, sotalol also has an ability to stop atrial fibrillation recurrence.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

100 mg in glass bottle

25 mg in poly bottle